Target intelligence / Profile preview

Long intergenic non-protein coding RNA 2431 (LINC02431)

Target
LINC02431
Molecular classification
Long intergenic non-coding RNA (lincRNA), Long non-coding RNA (lncRNA) family
01

Overview

Long intergenic non-protein coding RNA 2431 (LINC02431) is a member of the lincRNA subclass of long non-coding RNAs. LINC02431 is not translated into protein but is autonomously transcribed from a genomic region that does not overlap protein-coding genes[1][3][5]. LINC02431 is implicated as a potential biomarker for cancer diagnosis and prognosis, particularly lung cancer, where its altered expression can distinguish tumors from normal samples, suggesting roles in tumorigenesis and gene expression regulation[2]. Functional studies of other lincRNAs show that they typically regulate chromatin architecture, gene expression, and may act as scaffolds for protein complexes, but the precise mechanisms and biological roles of LINC02431 remain to be fully characterized[3][1].\n\nNo drugs or therapies currently target LINC02431 directly, and it is usually referenced by its canonical symbol and name in literature and databases. Research context points to its value as a diagnostic and prognostic biomarker in cancer, with further work necessary to clarify its roles and therapeutic potential[1][2][3].

Other names
LINC02431
02

Mechanism of action

Not directly applicable; as a lincRNA, it may be indirectly modulated by drugs that target epigenetic processes or gene expression regulators, but no established drugs act directly on LINC02431

03

Biological functions

Regulation of gene expression (chromatin remodeling, transcriptional regulation, RNA stabilization)Scaffold for protein or RNA complexesPossible enhancer-associated activityPotential involvement in cancer cell biology, including cell differentiation and tumorigenesis
04

Disease associations

Cancer (diagnostic biomarker, association with lung cancers, notably non-small cell lung cancer)Potential roles in other pathologies currently under research, but primarily studied in cancer context
05

Safety considerations

No specific therapeutic safety concerns documented, as direct targeting of LINC02431 is not clinically establishedGeneral challenges include off-target effects and delivery of RNA-targeted therapeutics
06

Biomarkers

Differential expression in tumor versus normal tissue (particularly in lung cancer)Prognostic biomarker for survival in cancer cohorts, primarily lung cancer datasets

Beyond the preview

Go deeper on Long intergenic non-protein coding RNA 2431 (LINC02431).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Long intergenic non-protein coding RNA 2431 (LINC02431).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call